| ||||||
| 3033 King George Hwy Ste 1A, Surrey, B.C., V4P1B8, CA. TEL: 604-542-0820 http://www.gnsbio.com | ||||||
| Last Sale | Net Change | % Change | Volume | Last Updated | ||
|---|---|---|---|---|---|---|
| $8.25 | unch | unch | N.A. | 11/21/08 1:42 PM ET | ||
| ||||||||||||||||||||||
 |
|
||||||||||||||||||||||
| ||||
| Security Type | Common Stock | Specialist | 833 | |
| Industry | Banks/Financial Services | Trading Post | 9 | |
| Primary Exchange | Amex | SEC Filings | ||
| ||||
| Description |
|
Genesis Bioventures, Inc., a biomedical corporation, focuses on facilitating the development and marketing of novel diagnostics, therapeutics and niche products. The company is also an investor in a portfolio company, which is involved in neurodegenerative diagnostics. The company's immediate development and acquisition efforts are focused on cancer diagnostic, therapeutic and neurodegenerative discoveries within the emerging field of proteomics (the identification of disease-specific proteins). As of Dec. 31, 2004, the company was primarily focused on the development and marketing of its breast cancer risk assessment tool, which has been directly licensed from the University of Michigan. Biomedical Diagnostics, LLC, a wholly owned subsidiary, is developing proprietary cancer screening products. The initial product development effort is the commercialization of the Mammastatin Serum Assay (MSA) as a risk screening diagnostic for breast cancer. Mammastatin is a protein that has been found to be present in the breast tissue of healthy women. Research has shown that mammastatin can be detected in the blood of over 85% of healthy women and is absent in the blood of over 90% of breast cancer patients. That research also shows that the concentration of mammastatin drops significantly both in women with breast cancer and in women at risk for breast cancer. Biomedical Diagnostics has developed the MSA test as a simple blood serum diagnostic that could measure the quantity of mammastatin in blood serum. The results from this test could be used to assess women's risk of developing breast cancer. The MSA is a blood test that measures mammastatin levels in serum samples using monoclonal antibody technology. Data from a clinical study which used the MSA test to measure mammastatin levels in blood samples have been analyzed and the results indicate that there is a statistically significant difference in the mammastatin levels between healthy women and breast cancer patients. |
| Quote |
| ||||
| Last Sale | $8.25 (11/21/08) | |||
| Net Change | unch | |||
| % Change | unch | |||
| Previous Close | $8.25 | |||
| Today’s Open | N.A. | |||
| Today’s High | N.A. | |||
| Today’s Low | N.A. | |||
| Volume | N.A. | |||
| 52 Week High | $10.40 | |||
| 52 Week Low | $3.55 | |||
| ||||
| Chart |
| 3mo | 6mo | 12mo | 24mo | 36mo | 48mo | 60mo |
|
| Click here to view the data behind the chart. |
| Fundamentals |
|
||||
| P/E ratio | N.A. | Short Interest | N.A. | |
| Earnings Per Share | N.A. | Current yield | N.A. | |
| Shares Outstanding | 2,350,000 | Dividend Info | ||
| Market Cap | 19,387,500 | |||
|
||||
|
|
